Table 1.
Demographic and clinical baseline characteristics for patients treated with rt-PA and patients treated with TNK
| All patients (n = 139) | rt-PA group (n = 65) | TNK group (n = 74) | p-value | |
|---|---|---|---|---|
| Age [years] (median (IQR)) | 73 (81–63) | 75 (82–65) | 73 (81–61) | 0.331 |
| Female sex (n (%)) | 59 (42.4) | 26 (40.0) | 33 (44.6) | 0.584 |
| Pre-stroke mRS (median (IQR)) | 1 (2–0) | 1 (1–0) | 1 (2–0) | 0.934 |
| Arterial hypertension n (%)) | 85 (61.2) | 43 (66.2) | 42 (56.8) | 0.257 |
| Diabetes mellitus (n (%)) | 27 (19.4) | 15 (23.1) | 12 (16.2) | 0.308 |
| Dyslipidemia (n (%)) | 91 (65.5) | 47 (72.3) | 44 (59.5) | 0.112 |
| Known atrial fibrillation (n (%)) | 6 (4.3) | 1 (1.5) | 5 (5.6) | 0.456 |
| Smoking (n (%)) | 14 (10.1) | 9 (13.8) | 5 (6.8) | 0.166 |
| Coronary artery disease (n (%)) | 23 (16.5) | 10 (15.4) | 13 (17.6) | 0.730 |
| Chronic heart failure (n (%)) | 35 (25.2) | 14 (21.5) | 21 (28.4) | 0.354 |
| Stroke etiology (n (%)) | ||||
|
- Cardioembolic - Large-artery disease - Small vessel disease - Other - Unkown |
35 (25.2) 28 (20.1) 13 (9.4) 4 (2.9) 59 (42.4) |
16 (24.6) 13 (20.0) 8 (12.3) 3 (4.6) 25 (38.5) |
19 (25.7) 15 (20.3) 5 (6.8) 1 (1.4) 34 (45.9) |
0.571 |
| Prior single antiplatelet treatment (n (%)) | 37 (26.6) | 18 (26.9) | 19 (26.4) | 0.949 |
| Prior dual antiplatelet treatment (n (%)) | 4 (2.9) | 2 (3.0) | 2 (2.8) | 1.000 |
| Prior oral anticoagulation (n (%)) | 2 (1.4) | 1 (1.5) | 1 (1.4) | 1.000 |
| NIHSS admission (median (IQR)) | 7 (11–4) | 7 (11–4) | 7 (10–4) | 0.473 |
| LVO (n (%)) | 45 (32.4) | 25 (38.5) | 20 (27.0) | 0.151 |
| Site of LVOa (n (%)) | ||||
|
- Intracranial ICA - MCA M1 - MCA M2 - ICA + MCA M1 - Carotid T - Basilar artery |
2 (4.4) 10 (22.3) 16 (35.6) 6 (13.3) 6 (13.3) 5 (11.1) |
1 (4.0) 5 (20.0) 9 (36.0) 1 (4.0) 5 (20.0) 4 (16.0) |
1 (5.0) 5 (25.0) 7 (35.0) 5 (25.0) 1 (5.0) 1 (5.0) |
0.227 |
| EVT (n (%)) | 41 (29.5) | 24 (36.9) | 17 (23.0) | 0.072 |
| Successful recanalizationb (mTICI 2b-3) (n (%)) | 40 (97.6) | 24 (100.0) | 16 (94.1) | 0.229 |
| Acute stenting during EVTb(n (%)) | 10 (24.4) | 5 (20.8) | 5 (29.4) | 0.529 |
| Tirofiban after stenting within 24 hoursb(n (%)) | 7 (17.1) | 4 (16.7) | 3 (17.6) | 1.000 |
| Other antiplatelets after stenting within 24 hoursb (n (%)) | 2 (4.9) | 0 (0.0) | 2 (11.8) | 0.166 |
mRS Modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, min Minutes, IVT Intravenous thrombolysis, LVO Large vessel occlusion, EVT Endovascular thrombectomy, IQR Interquartile range
aProportions refer to the overall number of patients with LVO in each group
bProportions refer to the number of patients treated by EVT in each group